These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 16740594

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Impaired cotranslational processing of the calcium-sensing receptor due to signal peptide missense mutations in familial hypocalciuric hypercalcemia.
    Pidasheva S, Canaff L, Simonds WF, Marx SJ, Hendy GN.
    Hum Mol Genet; 2005 Jun 15; 14(12):1679-90. PubMed ID: 15879434
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Calcium signaling regulates trafficking of familial hypocalciuric hypercalcemia (FHH) mutants of the calcium sensing receptor.
    Grant MP, Stepanchick A, Breitwieser GE.
    Mol Endocrinol; 2012 Dec 15; 26(12):2081-91. PubMed ID: 23077345
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The pathophysiology of primary hyperparathyroidism.
    Brown EM.
    J Bone Miner Res; 2002 Nov 15; 17 Suppl 2():N24-9. PubMed ID: 12412774
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Functional characterization of calcium-sensing receptor codon 227 mutations presenting as either familial (benign) hypocalciuric hypercalcemia or neonatal hyperparathyroidism.
    Wystrychowski A, Pidasheva S, Canaff L, Chudek J, Kokot F, Wiecek A, Hendy GN.
    J Clin Endocrinol Metab; 2005 Feb 15; 90(2):864-70. PubMed ID: 15572418
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Receptor-activity-modifying proteins are required for forward trafficking of the calcium-sensing receptor to the plasma membrane.
    Bouschet T, Martin S, Henley JM.
    J Cell Sci; 2005 Oct 15; 118(Pt 20):4709-20. PubMed ID: 16188935
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Glial cells missing-2 (GCM2) transactivates the calcium-sensing receptor gene: effect of a dominant-negative GCM2 mutant associated with autosomal dominant hypoparathyroidism.
    Canaff L, Zhou X, Mosesova I, Cole DE, Hendy GN.
    Hum Mutat; 2009 Jan 15; 30(1):85-92. PubMed ID: 18712808
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dominant-negative effects of episodic ataxia type 2 mutations involve disruption of membrane trafficking of human P/Q-type Ca2+ channels.
    Jeng CJ, Sun MC, Chen YW, Tang CY.
    J Cell Physiol; 2008 Feb 15; 214(2):422-33. PubMed ID: 17654512
    [Abstract] [Full Text] [Related]

  • 20. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.
    Ho C, Conner DA, Pollak MR, Ladd DJ, Kifor O, Warren HB, Brown EM, Seidman JG, Seidman CE.
    Nat Genet; 1995 Dec 15; 11(4):389-94. PubMed ID: 7493018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.